|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG006860311 |
| 003 |
DE-627 |
| 005 |
20230629100652.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2023 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG006860311
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2012-001314-42-DE
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)IM103116
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2012-001314-42-SE
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a A study for people who have had a kidney transplant to see the benefits and risks of taking belatacept instead of their current anti-rejection medicine.
|b Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversionto Nulojix® (belatacept)-based Immunosuppression
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 06-08-2013, Last updated: 2023-06-29
|
| 650 |
|
4 |
|a Medical Condition: Maintenance of renal transplant recipients MedDRA version: 20.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 21. Juni
|
| 773 |
1 |
8 |
|g year:2023
|g day:21
|g month:06
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001314-42
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 21
|c 06
|
Klinische Studie